Constrained peptide models from phage display libraries highlighting the cognate epitope-specific potential of the anti-HIV-1 mAb 2F5

Palacios, Yadira; Gazarian, Tatiana; Huerta, Leonor; Gazarian, Karlen

doi:10.1016/j.imlet.2010.12.008

Cited by 15 publications

(13 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The selected peptide was used as a vaccine in its soluble form or in conjugation with carrier proteins [ 55 , 66 , 70 , 81 , 82 , 83 , 84 , 86 , 87 , 88 , 90 , 91 , 92 , 98 ]. In the second sub-category, similar to the first sub-category, inovirus display technology has been used for epitope mapping and isolation, but in this case, inoviruses were also used as the vaccine carriers for the immunogenic peptides [ 48 , 49 , 50 , 51 , 52 , 53 , 54 , 56 , 57 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 67 , 68 , 69 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 ]. In contrast to IAVs, soluble peptides have the disadvantage of being less stable than the same peptides fused to inoviral particles.…”

Section: Inovirus Display Technology In Vaccine Design Against Nonmentioning

confidence: 99%

Architectural Insight into Inovirus-Associated Vectors (IAVs) and Development of IAV-Based Vaccines Inducing Humoral and Cellular Responses: Implications in HIV-1 Vaccines

Hassapis

Stylianou

Kostrikis

2014

Viruses

View full text Add to dashboard Cite

Inovirus-associated vectors (IAVs) are engineered, non-lytic, filamentous bacteriophages that are assembled primarily from thousands of copies of the major coat protein gp8 and just five copies of each of the four minor coat proteins gp3, gp6, gp7 and gp9. Inovirus display studies have shown that the architecture of inoviruses makes all coat proteins of the inoviral particle accessible to the outside. This particular feature of IAVs allows foreign antigenic peptides to be displayed on the outer surface of the virion fused to its coat proteins and for more than two decades has been exploited in many applications including antibody or peptide display libraries, drug design, and vaccine development against infectious and non-infectious diseases. As vaccine carriers, IAVs have been shown to elicit both a cellular and humoral response against various pathogens through the display of antibody epitopes on their coat proteins. Despite their high immunogenicity, the goal of developing an effective vaccine against HIV-1 has not yet materialized. One possible limitation of previous efforts was the use of broadly neutralizing antibodies, which exhibited autoreactivity properties. In the past five years, however, new, more potent broadly neutralizing antibodies that do not exhibit autoreactivity properties have been isolated from HIV-1 infected individuals, suggesting that vaccination strategies aimed at producing such broadly neutralizing antibodies may confer protection against infection. The utilization of these new, broadly neutralizing antibodies in combination with the architectural traits of IAVs have driven the current developments in the design of an inovirus-based vaccine against HIV-1. This article reviews the applications of IAVs in vaccine development, with particular emphasis on the design of inoviral-based vaccines against HIV-1.

show abstract

Section: Inovirus Display Technology In Vaccine Design Against Nonmentioning

confidence: 99%

Architectural Insight into Inovirus-Associated Vectors (IAVs) and Development of IAV-Based Vaccines Inducing Humoral and Cellular Responses: Implications in HIV-1 Vaccines

Hassapis

Stylianou

Kostrikis

2014

Viruses

View full text Add to dashboard Cite

show abstract

“…However, the induced antibodies did not exhibit neutralizing activity against HIV-1 [68]. Other RPLs screened against monoclonal and broadly neutralizing antibodies have produced antibodies that do not have neutralizing capabilities [55,70]. In one such case, crystallization of the specific mimotope revealed that the oligopeptide borne by the inovirus was structurally different that the natural antibody epitope [69].…”

Section: Inovirus Display Technology In Vaccine Designmentioning

confidence: 99%

“…For example as discussed above, despite extensive work with inoviruses beginning in 1993 by Keller et al [66], there has been very little success developing a (HIV-1) vaccine [95]. While four major epitopes on the HIV-1 envelope gp41 and gp120 glycoproteins have been identified [96][97][98], inducing the production of effective antibodies has not been successful [70]. While current techniques have not succeeded, both humoral and cellular responses to HIV-1 through inovirus-based vaccines are being researched [99,100].…”

Section: Inovirus Display Technology In Vaccine Designmentioning

confidence: 99%

“…While there have been many vaccine studies targeting HIV-1 using IAVs, none have been completely successful. Studies involving inovirus based-vaccines targeting HIV-1 initially only used the broadly neutralizing monoclonal antibodies 2F5, 2G12 and b12 [55,[66][67][68][69][70]. However, as discussed above, these studies have either failed to induce antibodies or induced non-neutralizing antibodies, despite often inducing a humoral response.…”

Section: Inovirus Display Technology In Vaccine Designmentioning

confidence: 99%

See 1 more Smart Citation

The development of inovirus-associated vector vaccines using phage-display technologies

Stern

Stylianou

Kostrikis

2019

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Inovirus-associated vectors (IAVs) are derived from bacterial filamentous viruses (phages). As vaccine carriers, they have elicited both cellular and humoral responses against a variety of pathogens causing infectious diseases and other non-infectious diseases. By displaying specific antigen epitopes or proteins on their coat proteins, IAVs have merited much study, as their unique abilities are exploited for widespread vaccine development. Areas covered: The architectural traits of filamentous viruses and their derivatives, IAVs, facilitate the display of specific antigenic peptides which induce antibody production to prevent or curtail infection. Inoviruses provide a foundation for cost-efficient large-scale specific phage display. In this paper, the development of different applications of inovirus-based phage display vaccines across a broad range of pathogens and hosts is reviewed. The references cited in this review were selected from established databases based on the authors' knowledge of the study subject. Expert commentary: The importance of phage-display technology has been recently highlighted by the Nobel Prize in Chemistry 2018 awarded to George P. Smith and Sir Gregory P. Winter. Furthermore, the symbiotic nature of filamentous viruses infecting intestinal F + E. coli strains offers an attractive platform for the development of novel vaccines that stimulate mucosal immunity ARTICLE HISTORY

show abstract

“…Based on this study, additional investigations were recently conducted on the BNtAb 2F5 epitope to assess the importance of structural constraints for MAb 2F5 recognition [26]. A linear 12-mer RPL and a constrained 7-mer RPL were screened against this antibody and all the sequences selected from the 12-mer RPL contained the D(K/R)W core motif, with flanking residues L, A and S present at different frequencies.…”

Section: Exploration Of Hiv-1 Epitope Landscapementioning

confidence: 99%

Phages and HIV-1: From Display to Interplay

Delhalle

Schmit

Chevigné

2012

IJMS

View full text Add to dashboard Cite

The complex hide-and-seek game between HIV-1 and the host immune system has impaired the development of an efficient vaccine. In addition, the high variability of the virus impedes the long-term control of viral replication by small antiviral drugs. For more than 20 years, phage display technology has been intensively used in the field of HIV-1 to explore the epitope landscape recognized by monoclonal and polyclonal HIV-1-specific antibodies, thereby providing precious data about immunodominant and neutralizing epitopes. In parallel, biopanning experiments with various combinatorial or antibody fragment libraries were conducted on viral targets as well as host receptors to identify HIV-1 inhibitors. Besides these applications, phage display technology has been applied to characterize the enzymatic specificity of the HIV-1 protease. Phage particles also represent valuable alternative carriers displaying various HIV-1 antigens to the immune system and eliciting antiviral responses. This review presents and summarizes the different studies conducted with regard to the nature of phage libraries, target display mode and biopanning procedures.

show abstract

Constrained peptide models from phage display libraries highlighting the cognate epitope-specific potential of the anti-HIV-1 mAb 2F5

Cited by 15 publications

References 48 publications

Architectural Insight into Inovirus-Associated Vectors (IAVs) and Development of IAV-Based Vaccines Inducing Humoral and Cellular Responses: Implications in HIV-1 Vaccines

Architectural Insight into Inovirus-Associated Vectors (IAVs) and Development of IAV-Based Vaccines Inducing Humoral and Cellular Responses: Implications in HIV-1 Vaccines

The development of inovirus-associated vector vaccines using phage-display technologies

Phages and HIV-1: From Display to Interplay

Contact Info

Product

Resources

About